68-2

78/110

) Maruyama H, Kato N: Advances in ultrasound diagnosis in chronic liver diseases. Clin Mol Hepatol, 2019; 25: 160-167.) Maruyama H, Shiina S: Contrast-Enhanced Ultrasonography: Is it an Ideal Tool for Hepa‑tocellular Carcinoma Surveillance? Quant Imaging Med Surg, 2019; 9: 1611-1614.) Kido H, Mizumura S, Funahashi K, Shibuya K, Urita Y, Terahara A: 6. Metabolic Tumor Volume and Total Lesion Glycolysis in PET/CT are Related with the Clinicopathological T Stage of Colorectal Cancer and Predict its Prognosis, Toho Journal of Medicine, 2019； 4: 170modifications in hepatic stem/progenitor cells, Stem Cells International, 2019; 2019: 9789240. doi: 10.1155/2019/9789240. eCollec‑tion 2019 13) Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N: Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocel‑lular carcinoma. BMC Cancer, 2019; 19: 1088. 14) Sato K, Taniki N, Kanazawa R, Shimizu M, Ishii S, Ohama H, Takawa M, Nagamatsu H, Imai Y, Shiina S: Efficacy and Safety of Deep Sedation in Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma, Adv Ther, 2019; 36: 344-354. 15) Maruta S, Ogasawara S, Ooka Y, Inoue M, Itokawa N, Obu M, Seki A, Haga Y, Okabe S, Itobayashi E, Atsukawa M, Azemoto R, Mizu‑moto H, Sugiura N, Maeda T, Kobayashi K, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: The real world practice of systemic therapies in patients with advanced hepato‑cellular carcinoma in Japan: what has changed since lenvatinib approval? J Hepatol, 2019; 70: E614-E615. 16) Shima Y, Ogasawara S, Ooka Y, Kobayashi K, Maruta S, Kanzaki H, Kanayama K, Maeda T, Kusakabe Y, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: Post progression survival in patients with intermediate-stage hepatocellular carci‑noma after receiving transarterial chemoem‑bolization, J Hepatol, 2019; 70: E75. 17) Yumita S, Ogasawara S, Ooka Y, Kobayashi K, Maruta S, Kanzaki H, Kanayama K, Maeda T, Kusakabe Y, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: Analysis of sorafenib-regorafenib sequen‑tial therapy in patients with advanced hepa‑tocellular carcinoma using baseline date of sorafenib, J Hepatol, 2019; 70: E90-E91. 18) Oura H, Ogasawara S, Ooka Y, Kobayashi K, Maruta S, Kanzaki H, Kanayama K, Maeda T, Kusakabe Y, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: Analysis of the relationship between serum creatinine / cystatin C ratio and muscle mass in patients with hepatocellular carci‑noma, J Hepatol, 2019; 70: E844. 19) Miura Y, Ogasawara S, Ooka Y, Kobayashi K, Maruta S, Kanzaki H, Kanayama K, Maeda T, Kiyono S, Kusakabe Y, Nakamura M, Suzuki E, Saito T, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: Transition to the era of direct-acting antiviral changes in the prognosis of patients with hepatitis C virus-related hepatocellular carcinoma, J Hepatol, 2019; 70: E842. 20) Kobayashi K, Maruyama H, Kiyono S, Kanayama K, Maruta S, Maeda T, Kanzaki H, Kusakabe Y, Saito T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Chiba T, Nakamura M, Nakamoto S, Yasui S, Kato N: Shear Wave Elastography for Skeletal Muscle: A Novel Approach to Insulin Resistance in Cirrhosis, J Hepatol, 2019; 71: E844. 21) Sensui M, Ogasawara S, Ooka Y, Kobayashi K, Maruta S, Kanzaki H, Kanayama K, Maeda T, Kusakabe Y, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: Survival among patients with advanced hepatocellular carcinoma in the pre-TKI versus TKI eras, J Hepatol, 2019; 70: E620.〈Reviews〉 1 2Clinical Oncology〈Original Articles〉 1